Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility

Journal of Clinical Microbiology

Volumn 51, Issue 9, 2013, Pages 3090-3093

  Datta, K ^a   Rhee, P ^a   Byrnes III, E ^a   Garcia Effron, G ^b   Perlin, D S ^c   Staab, J F ^a   Marr, K A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; STEROL 14ALPHA DEMETHYLASE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS LENTULUIS; BROTH DILUTION; CONTROLLED STUDY; CRYPTOCOCCUS GATTII; DRUG DETERMINATION; FUNGUS GROWTH; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NEOSARTORYA; NEOSARTORYA UDAGAWAE; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; AZOLES; COMMUNICABLE DISEASES, EMERGING; CRYPTOCOCCUS GATTII; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; NEOSARTORYA; NITRILES; NORTH AMERICA; PYRIDINES; TRIAZOLES;

EID: 84882742698     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01190-13     Document Type: Article

References (47)

1. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4:625-632.
2. Balajee SA, Nickle D, Varga J, Marr KA. 2006. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot. Cell 5:1705-1712.
3. Balajee SA, Gribskov J, Brandt M, Ito J, Fothergill A, Marr KA. 2005. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J. Clin. Microbiol. 43:5996-5999.
4. Yaguchi T, Horie Y, Tanaka R, Matsuzawa T, Ito J, Nishimura K. 2007. Molecular Phylogenetics of Multiple Genes on Aspergillus Section Fumigati Isolated from Clinical Specimens in Japan. Nippon Ishinkin Gakkai Zasshi 48:37-46.
5. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. 2008. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob. Agents Chemother. 52:1244-1251.
6. Vinh DC, Shea YR, Sugui JA, Parrilla-Castellar ER, Freeman AF, Campbell JW, Pittaluga S, Jones PA, Zelazny A, Kleiner D, Kwon-Chung KJ, Holland SM. 2009. Invasive aspergillosis due to Neosartorya udagawae. Clin. Infect. Dis. 49:102-111.
7. Symoens F, Haase G, Pihet M, Carrere J, Beguin H, Degand N, Mely L, Bouchara JP. 2010. Unusual Aspergillus species in patients with cystic fibrosis. Med. Mycol. 48(Suppl 1):S10-S16.
8. Katz ME, Dougall AM, Weeks K, Cheetham BF. 2005. Multiple genetically distinct groups revealed among clinical isolates identified as atypical Aspergillus fumigatus. J. Clin. Microbiol. 43:551-555.
9. Alhambra A, Catalan M, Moragues MD, Brena S, Ponton J, Montejo JC, del Palacio A. 2008. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev. Iberoam. Micol. 25:246-249.
10. Sugui JA, Vinh DC, Nardone G, Shea YR, Chang YC, Zelazny AM, Marr KA, Holland SM, Kwon-Chung KJ. 2010. Neosartorya udagawae (Aspergillus udagawae), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus? J. Clin. Microbiol. 48:220-228.
11. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, Hoang L, Leslie MJ, MacDougall L, Magill SS, Morshed MG, Marr KA. 2009. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg. Infect. Dis. 15:1185-1191.
12. Chaturvedi V, Chaturvedi S. 2011. Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol. 19:564-571.
13. Byrnes EJ, III, Bartlett KH, Perfect JR, Heitman J. 2011. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect. 13:895-907.
14. Byrnes EJ, III, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chaturvedi V, Bildfell RJ, May RC, Heitman J. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6:e1000850. doi:10.1371/journal .ppat.1000850.
15. Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R. 2007. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J. Antimicrob. Chemother. 60:312-316.
16. Chen YC, Chang SC, Shih CC, Hung CC, Luhbd KT, Pan YS, Hsieh WC. 2000. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn. Microbiol. Infect. Dis. 36: 175-183.
17. Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, Thakur R, Harris JR. 2012. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn. Microbiol. Infect. Dis. 73:144-148.
18. Thompson GR, III, Wiederhold NP. 2010. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170: 291-313.
19. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
20. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Thompson GR, III, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309-311.
22. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J. 2012. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob. Agents Chemother. 56:5898-5906.
23. Schwarz S, Silley P, Simjee S, Woodford N, van Duijkeren E, Johnson AP, Gaastra W. 2010. Assessing the antimicrobial susceptibility of bacteria obtained from animals. J. Antimicrob. Chemother. 65:601-604. (Editorial.)
24. Staab JF, Balajee SA, Marr KA. 2009. Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism. J. Clin. Microbiol. 47:2079-2083.
25. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50.
26. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Florl C, Martin-Mazuelos E, Meis J, Pelaez T, Pfaller MA, Turnidge J. 30 May 2013. Isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document): a multicenter study. Antimicrob. Agents Chemother. Epub ahead of print. doi:10.1128/AAC.00636-13.
27. Balajee SA, Weaver M, Imhof A, Gribskov J, Marr KA. 2004. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob. Agents Chemother. 48:1197-1203.
28. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ, Meyer W. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:17258-17263.
29. Byrnes EJ, III, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, Heitman J. 2009. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J. Infect. Dis. 199:1081-1086.
30. Kidd SE, Guo H, Bartlett KH, Xu J, Kronstad JW. 2005. Comparative gene genealogies indicate that two clonal lineages of Cryptococcus gattii in British Columbia resemble strains from other geographical areas. Eukaryot. Cell 4:1629-1638.
31. Iqbal N, DeBess EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, Chiller T, Lockhart SR. 2010. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J. Clin. Microbiol. 48:539-544.
32. Diaz MR, Boekhout T, Theelen B, Fell JW. 2000. Molecular sequence analyses of the intergenic spacer (IGS) associated with rDNA of the two varieties of the pathogenic yeast, Cryptococcus neoformans. Syst. Appl. Microbiol. 23:535-545.
33. Lindberg J, Hagen F, Laursen A, Stenderup J, Boekhout T. 2007. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg. Infect. Dis. 13:178-179.
34. Hagen F, van Assen S, Luijckx GJ, Boekhout T, Kampinga GA. 2010. Activated dormant Cryptococcus gattii infection in a Dutch tourist who visited Vancouver Island (Canada): a molecular epidemiological approach. Med. Mycol. 48:528-531.
35. Georgi A, Schneemann M, Tintelnot K, Calligaris-Maibach RC, Meyer S, Weber R, Bosshard PP. 2009. Cryptococcus gattii meningoencephalitis in an immunocompetent person 13 months after exposure. Infection 37: 370-373.
36. Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CH, Boekhout T. 2012. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg. Infect. Dis. 18:1618-1624.
37. Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF. 2010. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob. Agents Chemother. 54:5139-5145.
38. Guinea J, Bouza E. 2008. Isavuconazole: A New and Promising Antifungal Triazole for the Treatment of Invasive Fungal Infections. Future Microbiol. 3:603-615.
39. Livermore J, Hope W. 2012. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin. Drug Metab. Toxicol. 8:759-765.
40. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, Rodriguez-Tudela JL. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
41. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
42. Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P. 13 April 2013. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. Epub ahead of print. doi:10.1093/jac/ dkt075.
43. Mellado E, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. 2011. Role of Aspergillus lentulus 14-alpha sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob. Agents Chemother. 55:5459-5468.
44. Staab JF, Kahn JN, Marr KA. 2010. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob. Agents Chemother. 54:4992-4998.
45. Soares BM, Santos DA, Kohler LM, da Costa Cesar G, de Carvalho IR, dos Anjos Martins M, Cisalpino PS. 2008. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing. Rev. Iberoam. Micol. 25:242-245.
46. Byrnes EJ, III, Marr KA. 2011. The outbreak of Cryptococcus gattii in Western North America: epidemiology and clinical issues. Curr. Infect. Dis. Rep. 13:256-261.
47. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.